Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Replacing the replacements

GSK using Angiochem technology to shuttle enzymes across BBB

GlaxoSmithKline plc is planning to use peptide technology from Angiochem Inc. to develop next-generation enzyme replacement therapies that target the CNS without lessening their effects in the periphery. They could replace current drugs that address only non-CNS symptoms of lysosomal storage disorders.

Under a deal at the end of February, Angiochem will apply its engineered peptide compound (EPiC) technology to an enzyme replacement therapy provided by GSK.

Angiochem will develop the product through pre-IND testing, after which GSK has the option to take over development and commercialization. The deal also allows for expansion to include an undisclosed number of additional lysosomal storage disease targets.

The biotech is eligible to receive up to $31.5 million comprising an upfront

Read the full 1144 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers